Login / Signup

Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model.

Kyle RosenkeFrederick HansenBenjamin SchwarzFriederike FeldmannElaine HaddockRebecca RosenkeKent BarbianKimberly Meade-WhiteAtsushi OkumuraShanna LeventhalDavid W HawmanEmily E RicottaCatharine M BosioCraig MartensGreg SaturdayHeinrich FeldmannMichael A Jarvis
Published in: Nature communications (2021)
The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication is observed in animals when the drug is administered either beginning 12 h before or 12 h following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients.
Keyphrases
  • sars cov
  • respiratory syndrome coronavirus
  • machine learning
  • emergency department
  • risk assessment
  • big data
  • coronavirus disease
  • human health
  • adverse drug
  • deep learning